211 related articles for article (PubMed ID: 16386902)
1. Identification of a novel series of tetrahydrodibenzazocines as inhibitors of 17beta-hydroxysteroid dehydrogenase type 3.
Fink BE; Gavai AV; Tokarski JS; Goyal B; Misra R; Xiao HY; Kimball SD; Han WC; Norris D; Spires TE; You D; Gottardis MM; Lorenzi MV; Vite GD
Bioorg Med Chem Lett; 2006 Mar; 16(6):1532-6. PubMed ID: 16386902
[TBL] [Abstract][Full Text] [Related]
2. Identification of novel functional inhibitors of 17beta-hydroxysteroid dehydrogenase type III (17beta-HSD3).
Spires TE; Fink BE; Kick EK; You D; Rizzo CA; Takenaka I; Lawrence RM; Ruan Z; Salvati ME; Vite GD; Weinmann R; Attar RM; Gottardis MM; Lorenzi MV
Prostate; 2005 Oct; 65(2):159-70. PubMed ID: 15924334
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, biochemical evaluation and rationalisation of the inhibitory activity of a series of 4-hydroxyphenyl ketones as potential inhibitors of 17beta-hydroxysteroid dehydrogenase type 3 (17beta-HSD3).
Lota RK; Dhanani S; Owen CP; Ahmed S
Bioorg Med Chem Lett; 2006 Sep; 16(17):4519-22. PubMed ID: 16797984
[TBL] [Abstract][Full Text] [Related]
4. The design of novel 17beta-hydroxysteroid dehydrogenase type 3 inhibitors.
Vicker N; Sharland CM; Heaton WB; Gonzalez AM; Bailey HV; Smith A; Springall JS; Day JM; Tutill HJ; Reed MJ; Purohit A; Potter BV
Mol Cell Endocrinol; 2009 Mar; 301(1-2):259-65. PubMed ID: 18775469
[TBL] [Abstract][Full Text] [Related]
5. Development of hormone-dependent prostate cancer models for the evaluation of inhibitors of 17beta-hydroxysteroid dehydrogenase type 3.
Day JM; Tutill HJ; Foster PA; Bailey HV; Heaton WB; Sharland CM; Vicker N; Potter BV; Purohit A; Reed MJ
Mol Cell Endocrinol; 2009 Mar; 301(1-2):251-8. PubMed ID: 18786604
[TBL] [Abstract][Full Text] [Related]
6. Structure-based design, synthesis and in vitro characterization of potent 17beta-hydroxysteroid dehydrogenase type 1 inhibitors based on 2-substitutions of estrone and D-homo-estrone.
Möller G; Deluca D; Gege C; Rosinus A; Kowalik D; Peters O; Droescher P; Elger W; Adamski J; Hillisch A
Bioorg Med Chem Lett; 2009 Dec; 19(23):6740-4. PubMed ID: 19836949
[TBL] [Abstract][Full Text] [Related]
7. The UV-filter benzophenone-1 inhibits 17beta-hydroxysteroid dehydrogenase type 3: Virtual screening as a strategy to identify potential endocrine disrupting chemicals.
Nashev LG; Schuster D; Laggner C; Sodha S; Langer T; Wolber G; Odermatt A
Biochem Pharmacol; 2010 Apr; 79(8):1189-99. PubMed ID: 20005209
[TBL] [Abstract][Full Text] [Related]
8. 4,5-Disubstituted cis-pyrrolidinones as inhibitors of type II 17beta-hydroxysteroid dehydrogenase. Part 3. Identification of lead candidate.
Wood J; Bagi CM; Akuche C; Bacchiocchi A; Baryza J; Blue ML; Brennan C; Campbell AM; Choi S; Cook JH; Conrad P; Dixon BR; Ehrlich PP; Gane T; Gunn D; Joe T; Johnson JS; Jordan J; Kramss R; Liu P; Levy J; Lowe DB; McAlexander I; Natero R; Redman AM; Scott WJ; Town C; Wang M; Wang Y; Zhang Z
Bioorg Med Chem Lett; 2006 Sep; 16(18):4965-8. PubMed ID: 16806919
[TBL] [Abstract][Full Text] [Related]
9. Development of 3-substituted-androsterone derivatives as potent inhibitors of 17β-hydroxysteroid dehydrogenase type 3.
Maltais R; Fournier MA; Poirier D
Bioorg Med Chem; 2011 Aug; 19(15):4652-68. PubMed ID: 21741247
[TBL] [Abstract][Full Text] [Related]
10. 4,5-Disubstituted cis-pyrrolidinones as inhibitors of type II 17beta-hydroxysteroid dehydrogenase. Part 2. SAR.
Gunn D; Akuche C; Baryza J; Blue ML; Brennan C; Campbell AM; Choi S; Cook J; Conrad P; Dixon B; Dumas J; Ehrlich P; Gane T; Joe T; Johnson J; Jordan J; Kramss R; Liu P; Levy J; Lowe D; McAlexander I; Natero R; Redman AM; Scott W; Seng T; Sibley R; Wang M; Wang Y; Wood J; Zhang Z
Bioorg Med Chem Lett; 2005 Jun; 15(12):3053-7. PubMed ID: 15890515
[TBL] [Abstract][Full Text] [Related]
11. Substituted 6-phenyl-2-naphthols. Potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1): design, synthesis, biological evaluation, and pharmacokinetics.
Marchais-Oberwinkler S; Kruchten P; Frotscher M; Ziegler E; Neugebauer A; Bhoga U; Bey E; Müller-Vieira U; Messinger J; Thole H; Hartmann RW
J Med Chem; 2008 Aug; 51(15):4685-98. PubMed ID: 18630892
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, biochemical evaluation and rationalisation of the inhibitory activity of a range of 4-hydroxyphenyl ketones as potent and specific inhibitors of the type 3 of 17beta-hydroxysteroid dehydrogenase (17beta-HSD3).
Lota RK; Olusanjo MS; Dhanani S; Owen CP; Ahmed S
J Steroid Biochem Mol Biol; 2008 Jul; 111(1-2):128-37. PubMed ID: 18620056
[TBL] [Abstract][Full Text] [Related]
13. STX2171, a 17β-hydroxysteroid dehydrogenase type 3 inhibitor, is efficacious in vivo in a novel hormone-dependent prostate cancer model.
Day JM; Foster PA; Tutill HJ; Schmidlin F; Sharland CM; Hargrave JD; Vicker N; Potter BV; Reed MJ; Purohit A
Endocr Relat Cancer; 2013 Feb; 20(1):53-64. PubMed ID: 23132791
[TBL] [Abstract][Full Text] [Related]
14. Synthesis of 3-spiromorpholinone androsterone derivatives as inhibitors of 17β-hydroxysteroid dehydrogenase type 3.
Djigoué GB; Kenmogne LC; Roy J; Poirier D
Bioorg Med Chem Lett; 2013 Dec; 23(23):6360-2. PubMed ID: 24144853
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases.
Frotscher M; Ziegler E; Marchais-Oberwinkler S; Kruchten P; Neugebauer A; Fetzer L; Scherer C; Müller-Vieira U; Messinger J; Thole H; Hartmann RW
J Med Chem; 2008 Apr; 51(7):2158-69. PubMed ID: 18324762
[TBL] [Abstract][Full Text] [Related]
16. Coumarins as novel 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for potential treatment of prostate cancer.
Harada K; Kubo H; Tomigahara Y; Nishioka K; Takahashi J; Momose M; Inoue S; Kojima A
Bioorg Med Chem Lett; 2010 Jan; 20(1):272-5. PubMed ID: 19954971
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of human and rat 3beta-hydroxysteroid dehydrogenase and 17beta-hydroxysteroid dehydrogenase 3 activities by perfluoroalkylated substances.
Zhao B; Hu GX; Chu Y; Jin X; Gong S; Akingbemi BT; Zhang Z; Zirkin BR; Ge RS
Chem Biol Interact; 2010 Oct; 188(1):38-43. PubMed ID: 20619251
[TBL] [Abstract][Full Text] [Related]
18. Discovery of potent and orally bioavailable 17β-hydroxysteroid dehydrogenase type 3 inhibitors.
Harada K; Kubo H; Abe J; Haneta M; Conception A; Inoue S; Okada S; Nishioka K
Bioorg Med Chem; 2012 May; 20(10):3242-54. PubMed ID: 22512907
[TBL] [Abstract][Full Text] [Related]
19. Steroidal lactones as inhibitors of 17beta-hydroxysteroid dehydrogenase type 5: chemical synthesis, enzyme inhibitory activity, and assessment of estrogenic and androgenic activities.
Bydal P; Luu-The V; Labrie F; Poirier D
Eur J Med Chem; 2009 Feb; 44(2):632-44. PubMed ID: 18472187
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological evaluation of phenyl substituted 1H-1,2,4-triazoles as non-steroidal inhibitors of 17β-hydroxysteroid dehydrogenase type 2.
Al-Soud YA; Marchais-Oberwinkler S; Frotscher M; Hartmann RW
Arch Pharm (Weinheim); 2012 Aug; 345(8):610-21. PubMed ID: 22532378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]